S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:DBVT

DBV Technologies Competitors

$5.02
-0.38 (-7.04 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.91
Now: $5.02
$5.25
50-Day Range
$3.73
MA: $5.61
$6.57
52-Week Range
$1.35
Now: $5.02
$9.32
Volume235,999 shs
Average Volume977,862 shs
Market Capitalization$551.49 million
P/E RatioN/A
Dividend YieldN/A
Beta2.91

Competitors

DBV Technologies (NASDAQ:DBVT) Vs. KYMR, BCRX, BLUE, VCEL, SRRK, and OCGN

Should you be buying DBVT stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to DBV Technologies, including Kymera Therapeutics (KYMR), BioCryst Pharmaceuticals (BCRX), bluebird bio (BLUE), Vericel (VCEL), Scholar Rock (SRRK), and Ocugen (OCGN).

DBV Technologies (NASDAQ:DBVT) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Profitability

This table compares DBV Technologies and Kymera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DBV TechnologiesN/AN/AN/A
Kymera TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares DBV Technologies and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$14.75 million37.39$-172,020,000.00($2.33)-2.15
Kymera TherapeuticsN/AN/AN/AN/AN/A

Kymera Therapeutics has lower revenue, but higher earnings than DBV Technologies.

Analyst Recommendations

This is a summary of current ratings and target prices for DBV Technologies and Kymera Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DBV Technologies24302.11
Kymera Therapeutics02402.67

DBV Technologies presently has a consensus target price of $7.0714, suggesting a potential upside of 40.87%. Kymera Therapeutics has a consensus target price of $50.3333, suggesting a potential upside of 9.75%. Given DBV Technologies' higher probable upside, equities research analysts clearly believe DBV Technologies is more favorable than Kymera Therapeutics.

Insider & Institutional Ownership

32.5% of DBV Technologies shares are owned by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are owned by institutional investors. 15.3% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Volatility & Risk

BioCryst Pharmaceuticals has a beta of 3.03, suggesting that its stock price is 203% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500.

Insider and Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of DBV Technologies shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 15.3% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares BioCryst Pharmaceuticals and DBV Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62
DBV Technologies$14.75 million37.39$-172,020,000.00($2.33)-2.15

BioCryst Pharmaceuticals has higher revenue and earnings than DBV Technologies. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioCryst Pharmaceuticals and DBV Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%
DBV TechnologiesN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BioCryst Pharmaceuticals and DBV Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCryst Pharmaceuticals03802.73
DBV Technologies24302.11

BioCryst Pharmaceuticals currently has a consensus price target of $11.3750, indicating a potential upside of 4.17%. DBV Technologies has a consensus price target of $7.0714, indicating a potential upside of 40.87%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than BioCryst Pharmaceuticals.

Summary

BioCryst Pharmaceuticals beats DBV Technologies on 8 of the 14 factors compared between the two stocks.

DBV Technologies (NASDAQ:DBVT) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Valuation and Earnings

This table compares DBV Technologies and bluebird bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$14.75 million37.39$-172,020,000.00($2.33)-2.15
bluebird bio$44.67 million42.00$-789,610,000.00($14.31)-1.95

DBV Technologies has higher earnings, but lower revenue than bluebird bio. DBV Technologies is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for DBV Technologies and bluebird bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DBV Technologies24302.11
bluebird bio013402.24

DBV Technologies presently has a consensus target price of $7.0714, indicating a potential upside of 40.87%. bluebird bio has a consensus target price of $68.4667, indicating a potential upside of 145.05%. Given bluebird bio's stronger consensus rating and higher probable upside, analysts plainly believe bluebird bio is more favorable than DBV Technologies.

Profitability

This table compares DBV Technologies and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DBV TechnologiesN/AN/AN/A
bluebird bio-256.84%-45.78%-35.14%

Institutional and Insider Ownership

32.5% of DBV Technologies shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 15.3% of DBV Technologies shares are held by insiders. Comparatively, 3.6% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

DBV Technologies has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500.

Summary

DBV Technologies beats bluebird bio on 8 of the 14 factors compared between the two stocks.

DBV Technologies (NASDAQ:DBVT) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Institutional and Insider Ownership

32.5% of DBV Technologies shares are held by institutional investors. Comparatively, 93.1% of Vericel shares are held by institutional investors. 15.3% of DBV Technologies shares are held by company insiders. Comparatively, 4.3% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares DBV Technologies and Vericel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DBV TechnologiesN/AN/AN/A
Vericel0.12%0.13%0.10%

Earnings and Valuation

This table compares DBV Technologies and Vericel's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$14.75 million37.39$-172,020,000.00($2.33)-2.15
Vericel$117.85 million15.76$-9,660,000.00$0.18224.50

Vericel has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

DBV Technologies has a beta of 2.91, suggesting that its share price is 191% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, suggesting that its share price is 211% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for DBV Technologies and Vericel, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DBV Technologies24302.11
Vericel02602.75

DBV Technologies currently has a consensus price target of $7.0714, suggesting a potential upside of 40.87%. Vericel has a consensus price target of $49.00, suggesting a potential upside of 21.26%. Given DBV Technologies' higher possible upside, equities analysts plainly believe DBV Technologies is more favorable than Vericel.

Summary

Vericel beats DBV Technologies on 10 of the 14 factors compared between the two stocks.

DBV Technologies (NASDAQ:DBVT) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Institutional and Insider Ownership

32.5% of DBV Technologies shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 15.3% of DBV Technologies shares are held by company insiders. Comparatively, 24.6% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for DBV Technologies and Scholar Rock, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DBV Technologies24302.11
Scholar Rock00503.00

DBV Technologies presently has a consensus target price of $7.0714, suggesting a potential upside of 40.87%. Scholar Rock has a consensus target price of $61.60, suggesting a potential upside of 21.74%. Given DBV Technologies' higher probable upside, equities research analysts plainly believe DBV Technologies is more favorable than Scholar Rock.

Profitability

This table compares DBV Technologies and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DBV TechnologiesN/AN/AN/A
Scholar Rock-365.84%-80.16%-41.33%

Risk & Volatility

DBV Technologies has a beta of 2.91, suggesting that its share price is 191% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Valuation & Earnings

This table compares DBV Technologies and Scholar Rock's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$14.75 million37.39$-172,020,000.00($2.33)-2.15
Scholar Rock$20.49 million83.07$-51,000,000.00($1.85)-27.35

Scholar Rock has higher revenue and earnings than DBV Technologies. Scholar Rock is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Scholar Rock beats DBV Technologies on 8 of the 14 factors compared between the two stocks.

DBV Technologies (NASDAQ:DBVT) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Insider & Institutional Ownership

32.5% of DBV Technologies shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 15.3% of DBV Technologies shares are owned by insiders. Comparatively, 3.5% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares DBV Technologies and Ocugen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$14.75 million37.39$-172,020,000.00($2.33)-2.15
OcugenN/AN/A$-20,240,000.00($1.48)-6.06

Ocugen has lower revenue, but higher earnings than DBV Technologies. Ocugen is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for DBV Technologies and Ocugen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DBV Technologies24302.11
Ocugen01302.75

DBV Technologies presently has a consensus price target of $7.0714, indicating a potential upside of 40.87%. Ocugen has a consensus price target of $4.80, indicating a potential downside of 46.49%. Given DBV Technologies' higher probable upside, research analysts plainly believe DBV Technologies is more favorable than Ocugen.

Profitability

This table compares DBV Technologies and Ocugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DBV TechnologiesN/AN/AN/A
OcugenN/A-47.72%-30.78%

Risk and Volatility

DBV Technologies has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, meaning that its share price is 256% more volatile than the S&P 500.

Summary

DBV Technologies beats Ocugen on 7 of the 11 factors compared between the two stocks.


DBV Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.